jelmyto
Generic: mitomycin·Code: UGN-101
jelmyto: developed by 1 company · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| UroGen Pharma Ltd. (URGN) | Approved |
FDA Decisions
Approval1 INDICATIONS AND USAGE JELMYTO ® is indicated for the treatment of adult patients with low-grade Upper Tract Urothelial Cancer (LG-UTUC). JELMYTO is an alkylating drug indicated for the treatment of adult patients with low-grade Upper Tract Urothelial Cancer (LG-UTUC). ( 1 )(URGN)
Frequently asked questions
Who is developing jelmyto?
jelmyto is being developed by UroGen Pharma Ltd..
What is jelmyto's latest FDA decision?
The most recent tracked FDA decision for jelmyto is Approval for 1 INDICATIONS AND USAGE JELMYTO ® is indicated for the treatment of adult patients with low-grade Upper Tract Urothelial Cancer (LG-UTUC). JELMYTO is an alkylating drug indicated for the treatment of adult patients with low-grade Upper Tract Urothelial Cancer (LG-UTUC). ( 1 ), dated April 15, 2020.
Get deeper analysis on jelmyto
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis